Home Tools
Log in
Cart

JAK

The JAK-STAT signalling pathway is a chain of interactions between proteins in a cell, and is involved in processes such as immunity, cell division, cell death and tumour formation. There are 4 JAK proteins: JAK1, JAK2, JAK3 and TYK2. JAKs contains a FERM domain (approximately 400 residues), an SH2-related domain (approximately 100 residues), a kinase domain (approximately 250 residues) and a pseudokinase domain (approximately 300 residues). The kinase domain is vital for JAK activity, since it allows JAKs to phosphorylate (add phosphate groups to) proteins.
Signaling Pathways | Target | TargetMol
Cat. No. Product name CAS No. Purity Chemical Structure
T9195 SHR0302 1445987-21-2 99.11%
SHR0302
SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3, 4...
T5382 Ritlecitinib 1792180-81-4 99.1%
Ritlecitinib
Ritlecitinib (PF-06651600) is a potent JAK3-selective inhibitor (IC50: 33.1 nM).
T2709 TAK-901 934541-31-8 99.1%
TAK-901
TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others....
TN1059 Ganoderic acid B 81907-61-1 99.09%
Ganoderic acid B
Ganoderic acid B is a chemical marker in quality control of G. lucidum and related products. Ganoderic acid B-containing herbs has potential influence towards th...
T2156 WP1066 857064-38-1 99.07%
WP1066
WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3. WP1066 has ...
TQ0037 Abrocitinib 1622902-68-4 99.05%
Abrocitinib
Abrocitinib (PF-04965842) (PF-04965842) is a potent, specific and orally-active JAK1 inhibitor (IC50s: 29/803 nM for JAK1/2).
T12427 Brepocitinib P-Tosylate 2140301-96-6 98.99%
Brepocitinib P-Tosylate
Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).
T9251 Fedratinib hydrochloride hydrate 1374744-69-0 98.96%
Fedratinib hydrochloride hydrate
Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.
T4657 WHI-P97 211555-05-4 98.91%
WHI-P97
WHI-P97 is a rationally designed potent inhibitor of JAK-3. IC50 value: Target: JAK3 Treatment of mast cells with WHI-P97 inhibited the translocation of 5-lipoxy...
T13571 JAK-IN-10 916741-98-5 98.88%
JAK-IN-10
JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.
T22142 RO8191 691868-88-9 98.85%
RO8191
RO8191 (CDM-3008) (CDM-3008), an imidazonaphthyridine compound, is an agonist of interferon (IFN) receptor.
T3065 TG101209 936091-14-4 98.81%
TG101209
TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.
T20742 TG-89 936091-56-4 98.8%
TG-89
TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cer...
T11710 JAK-IN-5 2096999-92-5 98.78%
JAK-IN-5
JAK-IN-5 is a JAK inhibitor (Compound 283 from patent US20170121327A1).
T1849 Momelotinib 1056634-68-4 98.75%
Momelotinib
Momelotinib (LM-1149) is an orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with IC50 of 11 nM/18 nM. JAK1/2 inhibitor CYT387 comp...
T3080 Pyridone 6 457081-03-7 98.7%
Pyridone 6
Pyridone 6 (JAK Inhibitor)(CMP 6) is a potent and selective inhibitor of JAK1 (IC50=15 nM, murine JAK1), JAK2 (IC50=1 nM), JAK3 (Ki=5 nM), and Tyk2 (IC50=1 nM); ...
T2853 Curcumol 4871-97-0 98.57%
Curcumol
Curcumol ((-)-Curcumol), a pure monomer isolated extracted from Rhizoma Curcumaeis, has antitumor activities.
T4657L WHI-P97 HCl 211555-05-4(free base) T4657L 98.55%
WHI-P97 HCl 211555-05-4(free base)
WHI-P97 HCl is a potent and selective JAK-3 inhibitor. WHI-P97 had an estimated Ki value of 0.09 microM from modeling studies and a measured IC50 value of 2.5 mi...
T14687 Deucravacitinib 1609392-27-9 98.52%
Deucravacitinib
Deucravacitinib (BMS-986165) inhibits IL-12/23 and type I IFN pathways[1][2]. BMS-986165 is a highly selective, orally bioavailable allosteric TYK2 inhibitor for...
T3398 Icaritin 118525-40-9 98.50%
Icaritin
Icaritin (Anhydroicaritin) has hormone regulation activity and cardiovascular function improvement activity. Icaritin has anticancer activity, can induce S phase...
SHR0302
T9195
SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3, 4...
Ritlecitinib
T5382
Ritlecitinib (PF-06651600) is a potent JAK3-selective inhibitor (IC50: 33.1 nM).
TAK-901
T2709
TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others....
Ganoderic acid B
TN1059
Ganoderic acid B is a chemical marker in quality control of G. lucidum and related products. Ganoderic acid B-containing herbs has potential influence towards th...
WP1066
T2156
WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3. WP1066 has ...
Abrocitinib
TQ0037
Abrocitinib (PF-04965842) (PF-04965842) is a potent, specific and orally-active JAK1 inhibitor (IC50s: 29/803 nM for JAK1/2).
Brepocitinib P-Tosylate
T12427
Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).
Fedratinib hydrochloride hydrate
T9251
Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.
WHI-P97
T4657
WHI-P97 is a rationally designed potent inhibitor of JAK-3. IC50 value: Target: JAK3 Treatment of mast cells with WHI-P97 inhibited the translocation of 5-lipoxy...
JAK-IN-10
T13571
JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.
RO8191
T22142
RO8191 (CDM-3008) (CDM-3008), an imidazonaphthyridine compound, is an agonist of interferon (IFN) receptor.
TG101209
T3065
TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.
TG-89
T20742
TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cer...
JAK-IN-5
T11710
JAK-IN-5 is a JAK inhibitor (Compound 283 from patent US20170121327A1).
Momelotinib
T1849
Momelotinib (LM-1149) is an orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with IC50 of 11 nM/18 nM. JAK1/2 inhibitor CYT387 comp...
Pyridone 6
T3080
Pyridone 6 (JAK Inhibitor)(CMP 6) is a potent and selective inhibitor of JAK1 (IC50=15 nM, murine JAK1), JAK2 (IC50=1 nM), JAK3 (Ki=5 nM), and Tyk2 (IC50=1 nM); ...
Curcumol
T2853
Curcumol ((-)-Curcumol), a pure monomer isolated extracted from Rhizoma Curcumaeis, has antitumor activities.
WHI-P97 HCl 211555-05-4(free base)
T4657L
WHI-P97 HCl is a potent and selective JAK-3 inhibitor. WHI-P97 had an estimated Ki value of 0.09 microM from modeling studies and a measured IC50 value of 2.5 mi...
Deucravacitinib
T14687
Deucravacitinib (BMS-986165) inhibits IL-12/23 and type I IFN pathways[1][2]. BMS-986165 is a highly selective, orally bioavailable allosteric TYK2 inhibitor for...
Icaritin
T3398
Icaritin (Anhydroicaritin) has hormone regulation activity and cardiovascular function improvement activity. Icaritin has anticancer activity, can induce S phase...
1 2 3 4 5 6 7 8 9
TargetMol